Antiviral⁢ Treatment Fails to Slow Early-Stage Alzheimer’s, study Finds

Herpes Simplex Virus and Alzheimer’s Link Explored in Clinical ⁤Trial

Approximately 60% to 70% of Americans are infected with herpes simplex viruses (HSV), commonly causing cold sores (HSV1) and‍ genital herpes (HSV2). After initial symptoms subside, these viruses can lie dormant within the‍ nervous ⁢system, periodically reactivating and causing‍ flare-ups. Recent research⁢ has ⁢explored a potential link‍ between ⁤herpes infections‍ and Alzheimer’s disease.Autopsy studies have⁢ revealed HSV1 DNA frequently enough associated with amyloid plaques in the brains of individuals diagnosed with Alzheimer’s.Furthermore, some studies suggest that people treated for ⁤herpes infections may be less likely to develop Alzheimer’s later compared ⁢to untreated‍ HSV-positive individuals.

“Based on those previous studies, ⁢there was hope that valacyclovir could have an ⁣effect,” stated D.P. Devanand, MD, lead investigator of the trial, professor of psychiatry ‍and neurology, and director of geriatric psychiatry. “But no one ⁣had⁢ conducted a clinical ⁣trial to test the idea.”

Trial⁢ Details⁣ and⁢ Findings

To investigate this potential connection, a clinical trial was conducted involving 120 adults, ‍with an average age ⁣of⁤ 71. All participants had⁤ been diagnosed with early Alzheimer’s disease ⁤or mild cognitive impairment, with‍ imaging or blood tests confirming Alzheimer’s pathology. Crucially, all participants exhibited antibodies indicating past herpes infections, predominantly HSV1, with some also having HSV2.

Participants were randomly assigned to ⁣receive either daily pills containing valacyclovir, an⁢ antiviral medication, or a placebo. The researchers monitored participants’ memory⁢ functions and⁢ used⁢ brain⁢ imaging to detect amyloid and tau‍ deposits, hallmarks of Alzheimer’s, as well as other structural ⁣brain changes.

After 18 months,the study revealed no important benefits from valacyclovir treatment. In fact, participants taking ‍the placebo ‍performed‍ slightly better on cognitive tests than those receiving valacyclovir. Other⁤ measured outcomes showed no significant ⁣differences between the two groups.

“We were looking ⁢for ⁤a signal that the drug did better than the placebo, but there wasn’t any in this study,” Dr. Devanand ‍commented. “On the other measures, sometimes⁤ the⁤ placebo group did slightly better,⁢ sometimes the treatment group ⁤did slightly better.”

The trial’s results remained consistent across different ⁤age groups, sexes, and apolipoprotein E e4 (APOE e4) genetic ‍status,⁣ a known risk factor for Alzheimer’s.”Our trial ⁢suggests antivirals that target herpes are not effective in ⁣treating early Alzheimer’s and cannot be recommended to⁤ treat such patients with ⁢evidence of‍ prior HSV infection,” concluded Dr. ‍Devanand. “We do not know if long-term‍ antiviral medication treatment following herpes infection can prevent Alzheimer’s because prospective controlled trials have⁤ not been conducted.”

Source: Columbia University Irving Medical Center